iRhythm Technologies, Inc. (IRTC), a digital health care company, Wednesday said it has signed an agreement with BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, to develop and sell certain patented technology assets within ambulatory cardiac monitoring (ACM).Under the agreement, iRhythm has secured license to develop and sell BioIntelliSense's patented pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within iRhythm's ACM products and services.'We believe that the licensed technology from BioIntelliSense can advance our premium positioning within ACM and further enables us to enter other adjacent indications such as obstructive sleep apnea over time,' said Quentin Blackford, iRhythm's President and CEO.

。根据该协议，iRhythm已获得开发和销售BioIntelliSense专利脉搏血氧仪、加速度计和趋势非侵入性血压技术的许可，用于iRhythm的ACM产品和服务。”iRhythm总裁兼首席执行官昆汀·布莱克福德（QuentinBlackford）说：“我们相信，生物智能感知（BioIntelliSense）的许可技术可以推进我们在ACM中的高端定位，并进一步使我们能够随着时间的推移进入其他相邻的适应症，例如阻塞性睡眠呼吸暂停。”。

.

.

BioIntelliSense will receive an upfront payment, and will also be eligible for deferred, milestone payments. BioIntelliSense is also entitled to receive royalties on annual sales of products and services that include licensed rights in the home sleep testing field of use.Additionally, iRhythm has reaffirmed its 2024 annual outlook for revenue, gross margin, and adjusted EBITDA excluding this transaction.

BioIntelliSense将收到预付款，也有资格获得延期的里程碑付款。BioIntelliSense也有权获得产品和服务年度销售的版税，其中包括家庭睡眠测试使用领域的许可权。此外，艾瑞思重申了2024年的收入、毛利率和调整后的息税折旧摊销前利润（不包括这笔交易）前景。

The company does not expect to incur any material incremental development expenses in 2024, other than the acquired in-process research and development expense, associated with this transaction. For comments and feedback contact: editorial@rttnews.comBusiness News.

公司预计在2024年不会产生任何实质性的增量开发费用，但与本次交易相关的收购过程中研发费用除外。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股